📚Happy to share our work on #AI & machine learning in PLA2R associated membranous Nephropathy, in NDT, “Clinical Phenotypes and Renal Outcomes in PLA2R-Associated Membranous Nephropathy”
Published in Nephrology Dialysis Transplantation
@jingneph.bsky.social
academic.oup.com/ndt/advance-...
Published in Nephrology Dialysis Transplantation
@jingneph.bsky.social
academic.oup.com/ndt/advance-...
Clinical Phenotypes and Renal Outcomes in PLA2R-Associated Membranous Nephropathy: A Multi-Center Cohort Study with Unsupervised Cluster Analysis
AbstractBackground. Membranous nephropathy (MN) associated with phospholipase A2 receptor (PLA2R) antibodies is the most common cause of nephrotic syndrome
academic.oup.com
June 19, 2025 at 2:30 PM
📚Happy to share our work on #AI & machine learning in PLA2R associated membranous Nephropathy, in NDT, “Clinical Phenotypes and Renal Outcomes in PLA2R-Associated Membranous Nephropathy”
Published in Nephrology Dialysis Transplantation
@jingneph.bsky.social
academic.oup.com/ndt/advance-...
Published in Nephrology Dialysis Transplantation
@jingneph.bsky.social
academic.oup.com/ndt/advance-...
Teenager with nephrotic syndrome. Biopsy revealed unusual case of membranous nephropathy in a peds patient. PLA2R positive (IHC). PLA2R most common antigen in peds MN. EXT1/2 also common, SEMA3B less common. (pubmed.ncbi.nlm.nih.gov/38025223/) #renalpath #pathsky #nephsky
October 13, 2025 at 1:56 PM
Teenager with nephrotic syndrome. Biopsy revealed unusual case of membranous nephropathy in a peds patient. PLA2R positive (IHC). PLA2R most common antigen in peds MN. EXT1/2 also common, SEMA3B less common. (pubmed.ncbi.nlm.nih.gov/38025223/) #renalpath #pathsky #nephsky
#RenalPath: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R).
bit.ly/2xVkJzs (FREE)
bit.ly/2xVkJzs (FREE)
July 6, 2025 at 10:01 AM
#RenalPath: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R).
bit.ly/2xVkJzs (FREE)
bit.ly/2xVkJzs (FREE)
#RenalPath: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R).
bit.ly/2xVkJzs (FREE)
bit.ly/2xVkJzs (FREE)
November 30, 2025 at 5:00 PM
#RenalPath: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R).
bit.ly/2xVkJzs (FREE)
bit.ly/2xVkJzs (FREE)
Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report
https://buff.ly/3Qh7uyp
https://buff.ly/3Qh7uyp
February 6, 2025 at 4:47 PM
Pembrolizumab-Mediated Complete Remission of a PLA2R-Positive Paraneoplastic Membranous Nephropathy: A Case Report
https://buff.ly/3Qh7uyp
https://buff.ly/3Qh7uyp
Another chronic glomerulopathy case. EM stage IV of IV resorbed deposits in a pt with PLA2R+ Membranous nephropathy with persistent proteinuria. #renalpath #pathsky #nephsky
February 24, 2026 at 7:55 PM
Another chronic glomerulopathy case. EM stage IV of IV resorbed deposits in a pt with PLA2R+ Membranous nephropathy with persistent proteinuria. #renalpath #pathsky #nephsky
A retraction of a Frontiers in Immunology paper published by the company EuroImmun. In this paper, they appear to have photoshopped their antibody chips.
One would hope a manufacturer of lab chips has many chips lying around for a photo. Why photoshop them?
pubpeer.com/publications...
One would hope a manufacturer of lab chips has many chips lying around for a photo. Why photoshop them?
pubpeer.com/publications...
December 30, 2024 at 2:15 AM
A retraction of a Frontiers in Immunology paper published by the company EuroImmun. In this paper, they appear to have photoshopped their antibody chips.
One would hope a manufacturer of lab chips has many chips lying around for a photo. Why photoshop them?
pubpeer.com/publications...
One would hope a manufacturer of lab chips has many chips lying around for a photo. Why photoshop them?
pubpeer.com/publications...
#PodocyteConference pre-meeting keynote 3: Nicola Tomas on the role of autoantibodies in podocytopathies, spanning PLA2R to nephrin
June 10, 2025 at 12:42 PM
#PodocyteConference pre-meeting keynote 3: Nicola Tomas on the role of autoantibodies in podocytopathies, spanning PLA2R to nephrin
Not sure Gd-IgA is meaningful beyond an association
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
We need a good biomarker for IgAN given the impoartance of immunosuppression (vs non-specific therapies: RASi, Flozins, ERA)
But the Gd-IgA doesn’t seem so impressive to me?
journals.lww.com/cjasn/pages/...
#NephSky @asnpublications.bsky.social #CJASN
VA by @corinateodosiu.bsky.social
But the Gd-IgA doesn’t seem so impressive to me?
journals.lww.com/cjasn/pages/...
#NephSky @asnpublications.bsky.social #CJASN
VA by @corinateodosiu.bsky.social
November 19, 2025 at 2:37 AM
Not sure Gd-IgA is meaningful beyond an association
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
It’s not PLA2R or ANCA even as a biomarker
#NephJC
See bsky.app/profile/hswa...
Bx for new onset NS in an older adult. Serologic work up including SPEP/UPEP IFE negative. Bx shows membranous pattern with few double contours. IgG3-k restriction and mottle EM deposits c/w PGNMID with membranous predominant pattern. PLA2R- #renalpath #pathsky #nephsky
October 5, 2025 at 3:30 PM
Bx for new onset NS in an older adult. Serologic work up including SPEP/UPEP IFE negative. Bx shows membranous pattern with few double contours. IgG3-k restriction and mottle EM deposits c/w PGNMID with membranous predominant pattern. PLA2R- #renalpath #pathsky #nephsky
𝗜𝗦𝗡 𝗩𝗜𝗗𝗘𝗢 𝗔𝗕𝗦𝗧𝗥𝗔𝗖𝗧 𝗦𝗘𝗥𝗜𝗘𝗦: PLA2R-positive Membranous Nephropathy by Laser Microdissection and Mass Spectrometry in Patients with Negative Immunofluorescence for PLA2R on Kidney Biopsy. 2025 from @kidneyint.bsky.social
#VideoAbstract by @drsumanbehera.bsky.social & @dilushiwijay.bsky.social
#VideoAbstract by @drsumanbehera.bsky.social & @dilushiwijay.bsky.social
January 8, 2026 at 1:30 PM
𝗜𝗦𝗡 𝗩𝗜𝗗𝗘𝗢 𝗔𝗕𝗦𝗧𝗥𝗔𝗖𝗧 𝗦𝗘𝗥𝗜𝗘𝗦: PLA2R-positive Membranous Nephropathy by Laser Microdissection and Mass Spectrometry in Patients with Negative Immunofluorescence for PLA2R on Kidney Biopsy. 2025 from @kidneyint.bsky.social
#VideoAbstract by @drsumanbehera.bsky.social & @dilushiwijay.bsky.social
#VideoAbstract by @drsumanbehera.bsky.social & @dilushiwijay.bsky.social
Combined PLA2R-Ab testing with ELISA and IIF provided optimal test characteristics in making a non-invasive diagnosis of MN before or soon after kidney biopsy. Further studies needed to assess whether genetic data can augment this approach. bit.ly/CJASN0671
#ASNCJASN
@jarcyzphd.bsky.social
#ASNCJASN
@jarcyzphd.bsky.social
March 17, 2025 at 6:00 PM
Combined PLA2R-Ab testing with ELISA and IIF provided optimal test characteristics in making a non-invasive diagnosis of MN before or soon after kidney biopsy. Further studies needed to assess whether genetic data can augment this approach. bit.ly/CJASN0671
#ASNCJASN
@jarcyzphd.bsky.social
#ASNCJASN
@jarcyzphd.bsky.social
New case for a panel discussion
Type 1 DM 25 yo with nephrotic syndrome
Swelling managed in wrist initially treated with NSAID and prednisone by rheum
DM dx'd at age 15
126/55
Cr 0.7
Albumin 3.3
A1c 8.1%
PLA2r negative, C3, C4 low ANA DS-DNA and hepatitis HIV all negatiove
#GlomCon
Type 1 DM 25 yo with nephrotic syndrome
Swelling managed in wrist initially treated with NSAID and prednisone by rheum
DM dx'd at age 15
126/55
Cr 0.7
Albumin 3.3
A1c 8.1%
PLA2r negative, C3, C4 low ANA DS-DNA and hepatitis HIV all negatiove
#GlomCon
September 23, 2025 at 10:01 PM
New case for a panel discussion
Type 1 DM 25 yo with nephrotic syndrome
Swelling managed in wrist initially treated with NSAID and prednisone by rheum
DM dx'd at age 15
126/55
Cr 0.7
Albumin 3.3
A1c 8.1%
PLA2r negative, C3, C4 low ANA DS-DNA and hepatitis HIV all negatiove
#GlomCon
Type 1 DM 25 yo with nephrotic syndrome
Swelling managed in wrist initially treated with NSAID and prednisone by rheum
DM dx'd at age 15
126/55
Cr 0.7
Albumin 3.3
A1c 8.1%
PLA2r negative, C3, C4 low ANA DS-DNA and hepatitis HIV all negatiove
#GlomCon
Do we have a PLA2R result in this patient @karnephro.bsky.social? #ECNeph
June 30, 2025 at 4:30 PM
Do we have a PLA2R result in this patient @karnephro.bsky.social? #ECNeph
⚡️PLA2R antibody seropositivity doesn’t mean that we do not investigate for underlying malignancies.
Here is a Case Report showing PLA2rAb MN having Carcinoma Oesophagus
#ECNeph
@theisn.org @myadla.bsky.social @dramiliflores.bsky.social @arvindcanchi.bsky.social
Here is a Case Report showing PLA2rAb MN having Carcinoma Oesophagus
#ECNeph
@theisn.org @myadla.bsky.social @dramiliflores.bsky.social @arvindcanchi.bsky.social
June 30, 2025 at 4:57 PM
⚡️PLA2R antibody seropositivity doesn’t mean that we do not investigate for underlying malignancies.
Here is a Case Report showing PLA2rAb MN having Carcinoma Oesophagus
#ECNeph
@theisn.org @myadla.bsky.social @dramiliflores.bsky.social @arvindcanchi.bsky.social
Here is a Case Report showing PLA2rAb MN having Carcinoma Oesophagus
#ECNeph
@theisn.org @myadla.bsky.social @dramiliflores.bsky.social @arvindcanchi.bsky.social
🎯 Dans la GEM, le traitement dépend du risque :
🟢 Faible : PU <4g, PLA2R <50 ↘️ → soutien seul
🟠 Modéré : 4–8g, PLA2R 50–150 stable → suivi étroit
🔴 Élevé : >8g, PLA2R ≥150 ↗️, eGFR ↓ → IS 💉
🔄 Biopsie + thérapies ciblées si forme réfractaire
📚 https://pubmed.ncbi.nlm.nih.gov/36938069/
🟢 Faible : PU <4g, PLA2R <50 ↘️ → soutien seul
🟠 Modéré : 4–8g, PLA2R 50–150 stable → suivi étroit
🔴 Élevé : >8g, PLA2R ≥150 ↗️, eGFR ↓ → IS 💉
🔄 Biopsie + thérapies ciblées si forme réfractaire
📚 https://pubmed.ncbi.nlm.nih.gov/36938069/
June 9, 2025 at 12:30 PM
🎯 Dans la GEM, le traitement dépend du risque :
🟢 Faible : PU <4g, PLA2R <50 ↘️ → soutien seul
🟠 Modéré : 4–8g, PLA2R 50–150 stable → suivi étroit
🔴 Élevé : >8g, PLA2R ≥150 ↗️, eGFR ↓ → IS 💉
🔄 Biopsie + thérapies ciblées si forme réfractaire
📚 https://pubmed.ncbi.nlm.nih.gov/36938069/
🟢 Faible : PU <4g, PLA2R <50 ↘️ → soutien seul
🟠 Modéré : 4–8g, PLA2R 50–150 stable → suivi étroit
🔴 Élevé : >8g, PLA2R ≥150 ↗️, eGFR ↓ → IS 💉
🔄 Biopsie + thérapies ciblées si forme réfractaire
📚 https://pubmed.ncbi.nlm.nih.gov/36938069/
First report of daratumumab therapy in refractory THSD7A-positive membranous nephropathy.
First report of daratumumab therapy in refractory THSD7A-positive membranous nephropathy.
We read with great interest the manuscript of Ayub and colleagues who reported a case of PLA2R+-membranous nephropathy (MN) refractory to rituximab1. Despite complete B-cell depletion over six…
buff.ly
October 24, 2025 at 9:30 PM
First report of daratumumab therapy in refractory THSD7A-positive membranous nephropathy.
A positive anti-PLA2R antibody test is “virtually” diagnostic of a lesion of MN (but may not always be able to reliably distinguish primary and secondary forms) #ECNeph #MedSky #NephSky @kdjhaveri.bsky.social @dramiliflores.bsky.social @karnephro.bsky.social
June 30, 2025 at 4:29 PM
A positive anti-PLA2R antibody test is “virtually” diagnostic of a lesion of MN (but may not always be able to reliably distinguish primary and secondary forms) #ECNeph #MedSky #NephSky @kdjhaveri.bsky.social @dramiliflores.bsky.social @karnephro.bsky.social
4/10
Who were the patients? 👥
📍Mean age 50 years
📍78% PLA2R positive
Some patients appeared to have eGFR and proteinuria values outside the inclusion criteria at baseline; could this reflect changes between screening and randomization? 🤔
#NephJC #TenPostNephJC #NephSky
Who were the patients? 👥
📍Mean age 50 years
📍78% PLA2R positive
Some patients appeared to have eGFR and proteinuria values outside the inclusion criteria at baseline; could this reflect changes between screening and randomization? 🤔
#NephJC #TenPostNephJC #NephSky
June 24, 2026 at 1:00 AM
4/10
Who were the patients? 👥
📍Mean age 50 years
📍78% PLA2R positive
Some patients appeared to have eGFR and proteinuria values outside the inclusion criteria at baseline; could this reflect changes between screening and randomization? 🤔
#NephJC #TenPostNephJC #NephSky
Who were the patients? 👥
📍Mean age 50 years
📍78% PLA2R positive
Some patients appeared to have eGFR and proteinuria values outside the inclusion criteria at baseline; could this reflect changes between screening and randomization? 🤔
#NephJC #TenPostNephJC #NephSky
Clinical variables and antibody levels predict remission in PLA2R-membranous nephropathy over 3 or 6 months of treatment, with 3-month models allowing earlier assessment of response. bit.ly/CJASN0694
#ASNCJASN
#ASNCJASN
May 4, 2025 at 2:00 PM
Clinical variables and antibody levels predict remission in PLA2R-membranous nephropathy over 3 or 6 months of treatment, with 3-month models allowing earlier assessment of response. bit.ly/CJASN0694
#ASNCJASN
#ASNCJASN
#nephrotopo
La rémission spontanée dans la #GEM n’est pas rare, même avec une protéinurie élevée
📉 >4 g/j → 45 %
📉 >8 g/j → 34 %
📉 Prot. petit PM élevée → 25-30 %
🧪 Anti-PLA2R ↑ → 17-20 %
📌 D’où l’approche individualisée #KDIGO 2021
#Néphrologie #PLA2R #Proteinurie
La rémission spontanée dans la #GEM n’est pas rare, même avec une protéinurie élevée
📉 >4 g/j → 45 %
📉 >8 g/j → 34 %
📉 Prot. petit PM élevée → 25-30 %
🧪 Anti-PLA2R ↑ → 17-20 %
📌 D’où l’approche individualisée #KDIGO 2021
#Néphrologie #PLA2R #Proteinurie
June 5, 2025 at 3:30 PM
#nephrotopo
La rémission spontanée dans la #GEM n’est pas rare, même avec une protéinurie élevée
📉 >4 g/j → 45 %
📉 >8 g/j → 34 %
📉 Prot. petit PM élevée → 25-30 %
🧪 Anti-PLA2R ↑ → 17-20 %
📌 D’où l’approche individualisée #KDIGO 2021
#Néphrologie #PLA2R #Proteinurie
La rémission spontanée dans la #GEM n’est pas rare, même avec une protéinurie élevée
📉 >4 g/j → 45 %
📉 >8 g/j → 34 %
📉 Prot. petit PM élevée → 25-30 %
🧪 Anti-PLA2R ↑ → 17-20 %
📌 D’où l’approche individualisée #KDIGO 2021
#Néphrologie #PLA2R #Proteinurie
8/ ✨🎯This study studied the effectiveness and tolerability of a low-dose triple therapy regimen in patients with high-risk (KDIGO 2012) PLA2R ab-MN and the kinetics of the PLA2R ab response. Let’s take a look at VA by @brian_rifkin 🤩 www.kireports.org/article/S246...
January 25, 2025 at 7:21 AM
8/ ✨🎯This study studied the effectiveness and tolerability of a low-dose triple therapy regimen in patients with high-risk (KDIGO 2012) PLA2R ab-MN and the kinetics of the PLA2R ab response. Let’s take a look at VA by @brian_rifkin 🤩 www.kireports.org/article/S246...
